DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* DOMAIN THERAPEUTICS *


 

2001 - Alsace
Illkirch Graffenstaden
(near Strasbourg)
www.domaintherapeutics.com

 

Discovery, Drugs
Key words: Neurological disorders, Neurotransmitter modulation, GPCR, Neuroclide, Glutamate inhibitor, Utrophin inducer, Parkinson, Alzheimer, Schizophrenia, Diabetes
Mission: to discover and develop new treatments notably (but not only) for neurological and metabolic disorders, with an exclusive focus on GPCR-mediated neurotransmitter modulation
Clients: Prescribers Pharmas and Biotechs (own development up to phase III Preclinical candidate)
info@domaintherapeutics.com

Age: 15 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Neuville (Pascal) [co-founder, born 1964, Ph.D. molecular biology, ex-Transgene, Assistant Professor]
Sc.Dir.-CSO: Neuville (Pascal) & Bossi (Laura) [M.D. neurologist, ex-Sanofi, Synthélabo]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Sofinnova Partners, Auriga Partners, La Compagnie Financière de Rothschild, Siparex, AGF P.E., FCJE, Airfi (Alsace Inter Regio Fonds d'Investissement) and Alsace Création, plus Sam Eletr and Bernard Gilly
Communication: the company was named Faust Pharmaceuticals from inception till December 2008, with URL as www.faustpharma.com

Turnover (M€) : n.a.
Total funding (M€) : 29.3
Last funding (M€) : 2.1
Focus : CNS
Position : Clinical
Company confirm : 2-May-2011

 

History
DATEMILESTONETYPETIME
2011 .01 Partnering development agreement with Merck Serono for Parkinson’s Disease and other neurodegenerative diseases R&D [9 years]
2009 .11 Research : successful completion of the first milestone in its Research Agreement with Takeda Pharmaceutical R&D [8 years]
2008 .12 4th round-financing : 2.1 M€ by historical investors (AGF Private Equity, Auriga Partners, Edmond de Rothschild Investment Partners and Sofinnova Partners), followed by Airfi (Alsace Inter Regio Fonds d'Investissement) and Alsace Création, plus Sam Eletr and Bernard Gilly RFIND [7 years]
2008 .12 Company renamed as Domain Therapeutics (from Faust Pharmaceuticals), with Bernard Gilly as President ORGF [7 years]
2008 .01 Partnering research agreement with Takeda R&D [6 years]
2006 .10 3rd round-financing : 8.2 M€, by previous shareholders (bridge financing) RFINC [5 years]
2006 .02 Nomination : Thomas Seoh as CEO, taking over from founders ORGN [4 years]
2004 .12 Clinical trial (phase IIa) for FP0011 in ALS and Parkinson's disease (beginning) CLIN [3 years]
2004 .04 2nd round-financing : 16.0 M€, by La Compagnie Financière Ed. de Rothschild, Siparex, AGF P.E., FCJE, and previous investors RFINB [2 years]
2003 .12 Acquisition of Euroclide, with a target oriented technology platform ACQ+ [2 years]
2003 .03 Company move from Paris to Strasbourg, in the BioValley cluster ORGL [1 year]
2002 .02 1st round-financing : 3.0 M€, by Sofinnova Partners and Auriga Partners RFINA [0 year]
2001 .10 Company founded as Faust Pharmaceuticals by Maurice Israël, Pierre Potier (Taxotere innovator), Pascal Neuville, based in Paris ORGF [0 year]

Actualisation / Updating: 2-May-2011

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende